atrial fibrillation (AF). atrial fibrillation (AF)
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive a daily 10 mg tablet of empagliflozin (brand name: Gloripa), manufactured by Abidi Pharmaceutical Company. Administration begins
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 to 70 years who are candidates for coronary artery bypass graft surgery (coronary artery bypass grafting; CABG).
Exclusion criteria
Exclusion criteria: Patients with left ventricular dysfunction. Patients with left atrial enlargement. Patients with chronic kidney disease and a glomerular filtration rate (GFR) below 30 mL/min Patients with a history of atrial fibrillation. Patients with chronic obstructive pulmonary disease (COPD) Patients with a history of urinary tract infection (UTI). Patients with liver failure. Patients with mitral valve disease of more than moderate severity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome variable in this study is the occurrence of atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG). This variable is identified and documented by a cardiologist based on electrocardiographic (ECG) evidence and recorded episodes of atrial fibrillation within 48 to 72 hours postoperatively. Timepoint: Atrial fibrillation will be measured and recorded at the following time points:Before coronary artery bypass graft surgery (as baseline)48 hours after surgery72 hours after surgery. Method of measurement: Atrial fibrillation will be measured using a standard twelve-lead electrocardiogram device at the specified time points. Final diagnosis will be made by a cardiologist based on electrocardiogram interpretation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmadreza Assareh
Ahvaz University of Medical Sciences
Outcome results
None listed